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Joseph Babrowicz, MD,a and Anton N. Sidawy, MD, MPH,a Washington, DC
Background: Expanded polytetrafluoroethylene (ePTFE) bonded with heparin (HePTFE) has been reported to perform
equivalent to saphenous vein graft (SVG) for below-knee bypass. This series examines outcomes for tibial artery bypass
using HePTFE and SVG over a contemporaneous time period.
Methods: A retrospective analysis of prospectively collected data was conducted for 112 tibial bypasses (62 HePTFE, 50
SVG) performed from November 2006 to January 2009. Demographics for age, sex, race, diabetes mellitus, and
end-stage renal disease were similar. Indications for revascularization were also similar: disabling claudication, 9%; rest
pain, 25%; and tissue loss, 66%. The HePTFE group included more reoperative procedures (45% vs 26%). All HePTFE
bypasses were performed using an autologous vein patch at the distal anastomosis. Postoperative graft surveillance by
pulse examination, ankle-brachial index, and duplex ultrasound imaging occurred at 1, 3, 6, and 12 months. Follow-up
ranged from 1 to 12 months. Kaplan-Meier and Cox regression analysis evaluated results in patients with no missing
variables.
Results: HePTFE and SVG bypasses demonstrated no significant differences in target tibial artery distribution: anterior
tibial (15 vs 17), dorsalis pedis (4 vs 5), posterior tibial (22 vs 16), and peroneal (21 vs 12). Graft occlusion occurred in
19 patients (16.9%) during follow-up. Primary patency at 1 year was 75.4% for HePTFE and 86.0% for SVG. There was
no significant difference in primary patency due to sex (male, 78%; female, 84%), race (white, 82%; African American,
77%), or diabetes mellitus (no diabetes mellitus, 84%; diabetes mellitus, 76%). End-stage renal disease resulted in
decreased patency (57%), with an eightfold reduction (95% confidence interval, 1.8%-39.8%; P .006). SVG patients had
a lower risk of occlusion/death (95% confidence interval, 14.2%-94.5%; P > .05). Sixteen amputations were performed,
with no significant difference based on conduit.
Conclusions: This experience indicates a trend for single-segment quality saphenous vein to remain the conduit of choice
for tibial artery bypass compared with HePTFE. Factors relevant to decreased 1-year patency for the entire cohort were
end-stage renal disease and nonhealing ulceration as the indication for revascularization. Although relatively short-term,
these results do support HePTFE as a viable alternative conduit for patients with absent or poor quality saphenous vein
who need a tibial bypass. ( J Vasc Surg 2012;56:1008-14.)
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rDespite rapid advances in endovascular therapy, surgi-
cal bypass continues to play a role in lower extremity
revascularization for the critically ischemic limb. Expanded
polytetrafluoroethylene (ePTFE) is the most common
prosthetic conduit for lower limb revascularization. ePTFE
grafts have been used with relative success for above-knee
bypasses but have not performed as well below the knee.1-3
Past results were discouraging enough to prompt some to
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1008onsider primary amputation in patients who did not have
utogenous conduit for a below-knee bypass.4 Adjuvant
echniques have been developed to improve the perfor-
ance of below-knee prosthetic bypasses. These tech-
iques include the interposition of a biologic interface
sing venous tissue at the distal anastomosis as a vein patch
r cuff as well as the addition of an arteriovenous fistula.5-8
ptimization of graft hemodynamics with anastomotic
eometry has also been explored.9-11
Heparin bonding to the inner surface of the graft may
mprove prosthetic graft performance by decreasing lumi-
al thrombosis and the formation of myointimal hyperpla-
ia. Heparin bonding reduced platelet deposition in animal
nd human models and reduced thrombus formation on
he inner surface of the graft.12-15 A reduction in myointi-
al hyperplasia at the anastomotic site has also been dem-
nstrated in animal models.13,15 Clinical bypass results
ith heparin-bonded ePTFE (HePTFE) grafts have been
escribed in nonrandomized, retrospective trials from Eu-
ope.16,17 Although these trials included a limited experi-
nce with tibial bypass, they reported results superior to
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Volume 56, Number 4 Neville et al 1009those obtained using standard ePTFE, with 1-year patency
for below-knee popliteal bypass in the 80% range and 3-year
patency at 68%. A retrospective comparison between He-
PTFE and saphenous vein grafts (SVGs) for below-knee
bypass demonstrated higher patency rates for the HePTFE
conduit, although without reaching statistical signifi-
cance.18 In light of these results, we wished to evaluate our
own outcome for tibial artery bypass comparing HePTFE
and quality saphenous vein.
METHODS
This study is a retrospective analysis of prospectively
collected data for tibial bypasses performed from Novem-
ber 2006 to November 2009. The analysis was performed
under an Investigational Review Board protocol for medi-
cal record review. The review included all patients during
the study period who underwent a tibial bypass with He-
PTFE or single-segment great saphenous vein (ipsilateral or
contralateral) by the primary author (R.N.). An additional
55 tibial bypasses performed during the study period were
excluded from analysis due to use of arm vein, short saphe-
nous vein, composite vein, or lack of at least 1 year of
follow-up.
Patients who underwent bypass with HePTFE were
informed of the new graft characteristics with the implica-
tion of possible heparin-induced thrombocytopenia and
were entered into a prospective database monitoring peri-
operative platelet counts. All patients in the study cohort
had at least 1 year of follow-up, with a mean of 417 days
(range, 369-963 days), comprising 450 days for SVG and
390 days for HePTFE.
The review included 112 bypasses (62 HePTFE grafts
and 50 SVGs). All patients underwent preoperative vein
mapping of the ipsilateral and contralateral great saphenous
veins with duplex ultrasound imaging. A vein sized 2.0
mm on the preoperative assessment was considered ade-
quate for an attempt at bypass. This size was chosen to
make maximal use of the venous conduit. Our experience
has been that veins measuring 2.0 mm on preoperative
duplex ultrasound imaging can often be dilated to a usable
size with gentle intraoperative hydrostatic dilatation. If the
ipsilateral or contralateral saphenous vein was present and
intact on preoperative mapping, it was examined intraop-
eratively with gentle hydrostatic dilation using a standard-
ized vein solution (1000 mL Normosol-R [Hospira Inc,
Lake Forest, Ill], 5 mL heparin sodium 1000 U/mL, 4 mL
papaverine 30 mg/mL, 1 mL calcium chloride 10%).
Venous conduit was harvested with an open technique,
leaving intact skin bridges when possible, especially at the
knee and thigh levels. The HePTFE bypasses were per-
formed using a 6-mm externally reinforced HePTFE graft
(Propaten; W. L. Gore & Associates, Flagstaff, Ariz). The
distal vein patch technique was used as previously de-
scribed7 in each HePTFE bypass, with perioperative hepa-
rinization and conversion to oral warfarin before discharge
and a target international normalized ratio of between 1.8
and 3.0. Bleeding history or socioeconomic factors pre-
vented 10 HePTFE bypass patients (16%) from taking marfarin. These patients were given aspirin (n  10) and
lopidogrel (n  5).
None of the HePTFE grafts incorporated a distal arte-
iovenous fistula (“patchula”) as described as part of our
arger tibial bypass series.8 SVGs were performed using
psilateral (n 45) or contralateral great saphenous vein (n
5). All SVGs consisted of a single segment (no composite
rafts) used in a translocated (80%) or reversed (20%)
onfiguration. In translocated grafts, the vein was removed
rom its bed and used in a nonreversed direction with the
alves lysed with a Mills valvulotome after the proximal
nastomosis was performed. This allowed positioning of
he vein graft to maximize length, often in nonanatomic
unnels. The reversed configuration was chosen to avoid
he need for valve lysis when vein size did not create a
ismatch in diameters at the anastomoses proximally or
istally.
SVG patients were discharged on antiplatelet therapy
ith aspirin (81 mg). Perioperative antibiotic prophylaxis
ncluded continuation of the patient’s antibiotic regimen if
lready on intravenous antibiotics; otherwise, perioperative
efazolin was used for prophylaxis.
Postoperative graft surveillance was performed by pulse
xamination and ankle-brachial index (ABI) at 1, 3, 6, and
2 months. Duplex ultrasound scans were performed at 6
nd 12 months or at any time where pulses or ABI were
iminished. Our duplex ultrasound technique used modi-
ed Strandness criteria to monitor saphenous vein and
ePTFE grafts. With the patient supine and the limb of
nterest abducted, grafts were assessed in the sagittal view
ith color-flow duplex and spectral Doppler imaging. Spe-
ific areas in the order of interest were the inflow artery,
roximal anastomosis, body of the graft (proximal, middle,
istal), distal anastomosis, and the runoff artery. Peak sys-
olic velocity measurements150% of adjacent arterialized
egments indicated70% diameter reduction. In addition,
bsolute peak systolic velocity measurements 10 cm/s
ndicated impending graft failure.
We also considered the spectral Doppler profile to help
urther delineate proximal and distal anastomotic lesions.
n arteriogram was performed if lesions were discovered
uring follow-up surveillance by physical examination or
ltrasound assessment, and significant lesions were treated.
his approach led to arteriography in two SVGs and six
ePTFE grafts, with intervention to maintain patency.
econdary interventions included surgical patch angio-
lasty (n 6) and angioplasty with cutting balloon (n 2).
he need for a secondary intervention was considered a
ailure of primary patency.
All records included in the analysis had follow-up data
o a 12-month interval or documentation of the cause for
eing censored from further analysis (death, thrombosis).
he record analysis included demographic data, medical
omorbidities, indications, bypass anatomy, and prior by-
ass. End-stage renal disease (ESRD) in this series indicated
hat the patient required active hemodialysis. Diabetes mel-
itus was identified as patients requiring oral hypoglycemic
edication or insulin therapy. Indications included claudi-
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October 20121010 Neville et alcation (Rutherford 3), rest pain (Rutherford 4), nonheal-
ing ulceration (Rutherford 5), and gangrene (Rutherford
6).
Follow-up data were collected from the record of each
patient in the series, including survival function (death or
graft thrombosis), primary patency, and major amputation
rate. Major amputations included any amputation proximal
to a transmetatarsal level. Unfortunately, due to a change in
institution by the authors, lack of access to patient records
limited the ability to accurately determine assisted primary
or secondary patency. This is a major limitation of the
series.
Differences in patient group characteristics were ana-
lyzed using P values from a two-tailed t-test, the Fisher
generalized test, and a Fisher two-sided exact test, as ap-
propriate. Kaplan-Meier analysis was performed for survival
function, and Kaplan-Meyer analysis with log-rank analysis
was performed for primary patency rates at 1 year between
the HePTFE grafts and SVG grafts. Multivariate analysis
using Cox regression with the covariates of age, sex, race,
indication, diabetes mellitus, ESRD, and other compo-
nents of the medical history was used to evaluate results in
those patients who were not missing variables.
RESULTS
Demographics were similar between the two groups for
mean age, sex, and race (Table I). There were no statisti-
cally significant differences in hypertension or ESRD. The
incidence of diabetes mellitus was higher in the SVG group
but this did not reach statistical significance (Table II).
Indications for surgery included claudication, rest pain,
nonhealing ulceration, and gangrene. Disabling claudica-
tion was the indication for revascularization in 8.1% of the
HePTFE group (n 5) and in 10% of the SVG group (n
5).
Most patients presented with Rutherford class 4
symptoms, with 91.1% of the series presenting with an
indication of limb-threatening ischemia. A higher percent-
age of patients presented with gangrene in the SVG cohort
Table I. Patient demographics of the two bypass groups
Characteristicsa
HePTFE Vein
P(n  62) (n  50)
Age, years 70.7  13.7 63  11.0 .428b
Sex .647c
Male 40 (64.5) 31 (62.0)
Female 22 (35.5) 19 (38.0)
Race .425d
White 29 (46.8) 22 (44.0)
African American 32 (51.6) 26 (52.0)
Other 1 (1.6) 2 (4.0)
HePTFE, Heparin-bonded expanded polytetrafluoroethylene.
aContinuous data are shown as the mean  standard deviation; categoric
data as number (%).
bTwo-tailed t-test.
cTwo-tailed Fisher exact test.
dFisher generalized exact test.(P  .029), but total tissue loss (ulceration or gangrene) bas similar between the two groups (HePTFE bypasses,
4.5%; SVG, 70%). The subgroup of renal failure patients
n dialysis included 10 HePTFE bypasses (one rest pain,
ine tissue loss) and seven SVG grafts (one rest pain, six
issue loss).
There was a statistically significant difference in prior
ypass: 43.5% of the HePTFE patients had undergone a
rior attempt at bypass vs only 18.0% of the SVG group
P .016). The absence of saphenous vein in the HePTFE
roup was due to prior lower extremity bypass (43%),
oronary bypass (29%), vein stripping (12%), or poor-
uality vein (16%).
The average preoperative ABI was 0.43 in SVG and
.39 inHePTFE, which increased to 0.94 and 0.83, respec-
ively, at the first postoperative evaluation.
Analysis of bypass anatomy revealed that the HePTFE
roup had a higher number of proximal anastomoses to the
xternal iliac artery, 21% compared with 4% in the vein
roup. This indicated that length was not a limiting factor,
ith the use of the prosthetic graft allowing the proximal
nastomosis to be constructed at a more proximal location
o avoid previously scarred groins and redo operations
nvolving the groin area. This was not as common with vein
onduit in which length was a consideration. Correspond-
ngly, only 2% in the HePTFE group originated distally
rom the popliteal artery, with none from the profunda
emoris artery. In contrast, 10% of the SVG group origi-
ated from the popliteal artery, with 5% from the profunda
emoris to conserve length, allowing the use of venous
onduit.
Arterial outflow for the HePTFE grafts included the
nterior tibial in 31% (6% dorsalis pedis), posterior tibial in
5%, and peroneal in 34%. The SVG group included the
nterior tibial in 44% (dorsalis pedis in 10%), posterior tibial
n 32%, and peroneal bypasses 24%. Outflow anatomy did
ot differ significantly between the prosthetic and the vein
able II. Differences between the two bypass groups in
edical morbidity, indications for revascularization, and
istory of prior bypass
ariablea
HePTFE Vein
Pb(n  62) (n  50)
orbidity
Hypertension 45 (72.6) 31 (62.0) .177
Diabetes mellitus 29 (46.8) 30 (60.0) .150
ESRD 8 (12.9) 9 (18.0) .454
evascularization for
Claudication 5 (8.1) 5 (10.0) .133
Rest pain 17 (27.4) 10 (20.0) .283
Nonhealing ulcer 30 (48.4) 22 (44.0) .075
Gangrene 10 (16.1) 13 (26.0) .029
Tissue loss, % 64.5 70.0
istory
Prior bypass 27 (43.5) 9 (18.0) .016
SRD, End-stage renal disease; HePTFE, heparin-bonded expanded poly-
etrafluoroethylene.
Data are shown as the number (%) or as indicated.
Fisher two-sided exact test.ypass groups.
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Volume 56, Number 4 Neville et al 1011Perioperative wound complications occurred in three
patients. One HePTFE patient developed a groin hema-
toma requiring drainage, and two SVG patients required
minor debridement of the vein harvest incision.
In follow-up there were 19 graft occlusions (seven
SVG, 12 HePTFE) and three deaths, for a 19.6% decreased
survival function rate in the form of graft occlusion or death
for the study cohort. Multivariate analysis produced a
model in which a set of predictors could be significantly
associated with this outcome (2 28.09, P .013). This
analysis identified two factors with significance for de-
creased survival function: ESRD (P .001) and ulcer as an
operative indication (P  .01; Table III). Patients with
ESRD had an 86% higher risk of death or graft thrombosis
(95% confidence interval [CI], 64%-245%), whereas ulcer-
ation as an indication for revascularization carried a 56%
higher risk (95% CI, 42%-114%). The wide CIs reflect the
relatively small sample size in each group.
Analysis of primary patency for the cohort demon-
strated no significant difference due to gender (P  .22),
race (white vs African American, P  .73), or diabetes
mellitus (P  .27). ESRD resulted in decreased 1-year
patency (57.1% vs 83.2% for no ESRD), a 57% or eightfold
reduction (95% CI, 1.8%-25.6%; P  .004). Logistic re-
gression modeling attributed 14% of the variance in pri-
mary patency outcome to ESRD and ulceration as an
indication. Each of these predictors was associated with
patency after accounting for the effects of the other two
predictors (P  .05 for ulcer, P  .01 for ESRD). The
1-year primary patency was highest for the claudicant pa-
tients (95.2% vs 76.7% nonclaudicant patients) compared
with primary patency in patients with rest pain (81.8%),
gangrene (71.4%), and ulcer (72.9%). The bypasses of the
five claudicant patients in the HePTFE cohort were patent
at 6 and 12 months, with one graft occlusion at 18 months.
This patient experienced recurrent claudication but no
limb-threatening ischemia.
Graft thrombosis occurred in 12 HePTFE grafts and
seven SVG. This resulted in a 1-year primary patency by
conduit of 86.0% for SVG and 75.4% for HePTFE. This
Table III. Multivariate analysis of predictors possibly asso
Parameter Parameter estimate SE
Age 0.03202 0.02884
Claudication 2.22202 1.25710
Rest pain 0.46503 0.57144
Gangrene 0.79075 0.63955
Ulcer 1.27015 6.63890
Sex 0.19321 0, 58454
Race 0.32991 0.57343
Diabetes 1.04470 0.66220
Renal failure 1.92509 0.67127
Hypertension 0.88294 0.67119
Previous bypass 0.57868 0.65310
CL, Confidence limits; HR, hazard ratio; Pr, probability; SE, standard error
aTwo factors were identified with significance for decreased graft survival fudifference did not reach statistical significance (P  .105; pig 1, A and B). Graft infection occurred in four HePTFE
rafts (6.5%) at 3, 4, 9, and 12 months. The original
evascularization in three of these patients had been for
onhealing open wounds. Standard perioperative antibi-
tic prophylaxis was used in these patients, with three of the
our patients taking a long-term multidrug regimen for the
resenting wound. Three of the infected grafts presented as
ccluded and were excised, resulting in two amputations.
he fourth infected graft occurred at 12months in a patient
d with graft survival (death or occlusion)
2 Pr 2 HR (95% CL)
1.2322 0.2670 1.033 (0.976, 1.093)
3.1243 0.0771 0.108 (0.009, 1.274)
0.5024 0.4785 0.667 (0.218, 2.044)
1.5287 0.2163 2.265 (0.630, 7.723)
3.9573 0.0467a 1.561 (1.019, 12.448)
0.1093 0.7410 0.824 (0.262, 2.592)
0.3310 0.5651 0.719 (0.234, 2.212)
2.4889 0.1147 2.843 (0.776, 10.408)
8.2245 0.0041a 6.856 (1.839, 25.553)
1.7305 0.1883 0.414 (0.111, 1.541)
0.7851 0.3756 1.784 (0.496, 6.416)
: end-stage renal disease and ulcer as an operative indication.
ig 1. Kaplan-Meier survival curves with log-rank analysis show
rimary patency over 12 months by graft type. The error bars show
he 95% confidence interval. Survival functions for patency be-
ween graft types did not differ significantly. DF, Degrees of
reedom;HePTFE, heparin-bonded expanded polytetrafluroethyl-
ne; Pr, probability.
Total Failed Censored Censored Occluded
ePTFE 62 11 51 82.26 17.74
ein 50 7 43 86.00 14.00
otal 112 18 94 83.93 16.07
est of equality over strata Test 2 DF Pr 2
Log-rank 0.2231 1 0.6367ciate
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October 20121012 Neville et aldrainage, debridement, and a sartorius muscle flap for
coverage. There were 16 amputations (14.3%) during the
observation period, with no difference by conduit type
(HePTFE group, 9; SVG group, 7). The mean time to
amputation was 4.9  6.7 months (HePTFE, 4.9  7.9
months; SVG, 5.0  5.3 months; P  .74). Multivariate
analysis revealed that gangrene as a presenting indication
raised the risk of amputation by 39% (95% CI, 17%-130%;
P  .01), and nonhealing ulcer increased amputation risk
by 20% (95%CI, 4%-85%; P .06). The type of conduit did
not lead to a difference in amputation risk (Fig 2).
DISCUSSION
Autogenous vein is the acknowledged ideal conduit for
distal bypass, but there is a growing group of patients that
lack vein for bypass or have a disadvantaged vein that results
in a high-risk bypass. This scenario has been identified as
those vein grafts with a diameter 3 mm, spliced vein
segments, or a nonsaphenous vein conduit.19 Morbidity
from vein harvest is not insignificant, especially when great
saphenous vein is not available and construction of a venous
conduit requires harvesting several segments, including
arm and short saphenous vein.20,21 Operative time is also
increased compared with bypass with a prosthetic conduit
through two limited incisions. Improvement in outcome
with prosthetic grafts may create an option for patients who
Fig 2. Kaplan-Meier survival curves with log-rank analysis show
amputation over 12 months by graft type. The error bars show the
95% confidence interval. Amputation risk did not differ signifi-
cantly between graft types. DF, Degrees of freedom; HePTFE,
heparin-bonded expanded polytetrafluroethylene; Pr, probability.
Total Failed Censored Censored Amputation
HePTFE 62 9 54 87.10 12.90
Vein 50 7 43 86.00 14.00
Total 112 16 97 86.61 14.30
Test of equality over strata Test 2 DF Pr 2
Log-rank 0.0067 1 0.9346lack autogenous material or have disadvantaged vein. pAttempts to improve the performance of prosthetic
rafts for below-knee bypass, especially to the tibial arteries,
ave included modifications in bypass technique, such as
uffs and patches, and changes in graft technology such as
eparin bonding. Heparin bonding using the Carmeda
ioactive surface technology (Carmeda, Upplands Vasby,
weden) allows binding of the heparin molecule to the
uminal surface of ePTFE grafts while maintaining the
orphology of the heparin molecule and hence its bioac-
ivity for at least 16 weeks.12 This process leads to a reduc-
ion in platelet deposition on the graft surface in animal and
uman models.12-15 Heparin bonding also has reduced
hrombus formation on the surface of the graft with a
ubsequent decrease in graft thrombogenicity in acute and
hronic models.12,14,22 A reduction in myointimal hyper-
lasia at the anastomotic site has been demonstrated with
eparin-bonded biomaterial surfaces.13,15,22 Decreased
latelet adherence, thrombus formation, and inhibition of
yointimal hyperplasia could be hypothesized to decrease
oth early and late graft failure.
Early trials reported results with HePTFE grafts for
elow-knee bypass with only a limited tibial experience:
● Peeters et al23 reported 2-year patency rates of 73% for
below-knee bypass and 69% for tibial bypass using
HePTFE.
● Lösel-Sadée and Alefelder24 reported patency specifi-
cally for tibial bypass, finding 64% patency at 1 year for
tibial bypasses using HePTFE.
● Comparing HePTFE and vein for below-knee bypass,
Battaglia et al25 noted that vein graft patency was
significantly better in patients with single-artery runoff
and more severe symptoms at initial presentation.
● Daenens andNevelsteen18 reported higher patency for
HePTFE vs vein grafts in below-knee bypasses and
concluded that HePTFE should be routinely consid-
ered for below-knee bypass.
● Dorigo et al26 compared primary patency for in situ
vein, standard PTFE, and HePTFE in a below-knee
bypass experience, with patency rates at 18 months of
75% for vein, 40% for standard PTFE, and 53% using
HePTFE. This represented a 57% reduction in early
graft thrombosis when using HePTFE, but results
remained inferior compared with saphenous vein con-
duit.26
● Similar results were obtained on a larger scale, as
reported by the Italian Registry Group,27 with HePTE
patency of 75% at 1 year and 61% at 3 years. This group
is engaged in a multicenter, prospective study to over-
come the limitations of the retrospective studies re-
ported to date.
The purpose of this study was to focus on tibial artery
ypass to define results in that patient subgroupmost apt to
eveal differences due to the conduit used. During the
tudy period, 112 tibial bypass procedures were identified,
ith 90% of the patients presenting with limb-threaten-
ng ischemia. The HePTFE group did have a higher rate of
rior bypass, which is not unexpected because the chance of
s
c
s
r
T
d
b
l
i
i
c
n
c
n
a
g
d
t
l
m
n
s
p
t
s
f
C
t
n
q
H
t
g
a
v
A
C
A
D
W
C
F
S
O
O
R
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 4 Neville et al 1013adequate saphenous vein being present at the time of repeat
bypass would be less in reoperative patients. There was also
a trend toward more vein grafts to the dorsalis pedis and
more HePTFE grafts to the peroneal artery, possibly a
result of this reoperative group having the peroneal artery
as the only remaining option.
Although there was no statistically significant differ-
ence in graft patency between the two groups at 1-year
follow-up, these short-term results reflect a trend toward
improved graft performance with quality venous conduit.
There was no difference in major amputation based on the
conduit used for bypass, although gangrene upon initial
presentation was associated with a higher rate of minor and
major amputation.
The rate of graft infection (6.5%) was not insignificant
and occurred primarily in patients with chronic, nonhealing
wounds. Aggressive debridement and rapid wound closure
may be important after HePTFE bypasses performed for
open ulceration to minimize graft infection.
Diabetes mellitus did not affect outcome, but patency
was decreased in patients who required active hemodialysis.
Primary patency was also decreased in patients with non-
healing ulceration as the indication for revascularization.
These findingsmay help identify patient subgroups (ESRD,
nonhealing ulcer) in which it is most important to use
autogenous conduit for the best outcomes, even if the vein
is disadvantaged in size or quality.
Although prospective, randomized data would be ideal,
attempts at such a study have been difficult to institute and
bring to fruition. The PRODIGY (Comparison of Primary
Patency between Propaten Vascular Graft and Disadvantaged
Autologous Vein Graft for Below-Knee Arterial Bypass) trial
was an attempt at a multicenter, prospective, randomized
comparison betweenHePTFE and SVG. The SVG armof the
trial was defined as “disadvantaged” saphenous vein, includ-
ing diameter3.0 mm, inadequate length, venous segments
other than saphenous vein, and sclerotic or phlebitic saphe-
nous vein.
Patients were enrolled in the study by the need for
distal bypass after compliance with specific inclusion and
exclusion criteria. Upon enrollment, patients were identi-
fied by examination and Duplex ultrasound imaging as
having quality or “disadvantaged” vein. Patients with qual-
ity saphenous vein were entered into a data collection
registry. Patients with “disadvantaged” vein were random-
ized to HePTFE or vein bypass. This was done to allow
consideration of all patients into the trial, but study orga-
nizers did not believe there was clinical equipoise to ran-
domize quality saphenous vein with prosthetic conduit for
tibial bypass. Over 2 years, 17 sites randomized 31 patients,
with an additional 25 enrolled in the adjunct data collection
arm.
The study was discontinued because of poor enroll-
ment, possibly due to the increase in tibial endovascular
interventions or an unwillingness to randomize SVGs with
prosthetic conduit. Given the difficulties of such a prospec-
tive, randomized analysis, clinical decisions regarding tibial
bypass will need to rely on the type of data presented in thiseries and those previously reported to guide surgeon’s
hoice of bypass conduit.
This experience with heparin-bonded ePTFE grafts for
olely tibial artery bypass yielded patency and limb salvage
ates that are comparable to intact great saphenous vein.
his study shares those limitations found in similar nonran-
omized, retrospective investigations and is further limited
y its short observation period. However, this is a relatively
arge comparison of exclusively tibial bypasses and some
nsights may be possible.
We believe that a quality saphenous vein remains the
deal conduit for tibial bypass, althoughHePTFE should be
onsidered when intact ipsilateral or contralateral vein is
ot available. In our practice, HePTFE has emerged as the
hoice over arm vein, especially in the ESRD patient who
eeds upper extremity vein for dialysis access. We would
lso choose HePTFE over composite short saphenous vein
iven the increased dissection required and length of con-
uit. Consideration would be given to these alternate au-
ogenous conduits in a relatively younger patient with a
onger anticipated life span or the patient with any docu-
ented hypercoagulability. The decreased graft patency
oted for patients on hemodialysis would also suggest
trong consideration for an autogenous conduit in this
opulation. Diabetes mellitus did not seem to affect pa-
ency in the same way, and therefore, diabetic patients
hould not be excluded from prosthetic revascularization
or limb salvage.
ONCLUSIONS
The primary patency and amputation rates achieved for
ibial bypass with heparin-bonded ePTFE and great saphe-
ous vein in this series support the concept that an intact,
uality vein remains the preferred conduit for distal bypass.
owever, results with heparin-bonded ePTFE suggest that
his conduit is an effective alternative choice when a suitable
reat saphenous vein is unavailable for tibial bypass. Further
ssessment will continue as long-term patency and limb sal-
age data accumulate.
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